Clinical trials: Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Despite advances in lung transplantation, the median survival remains only 55% at 5 years. The main limitation to long term survival is the development of chronic lung allograft dysfunction.
- Trial name
- PIRCLAD (NCT03359863)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco